Global Antivenom Market By Type Overview
Introduction:
Anti-venom is a medicine used for the treatment of bite from poisonous animals such as snake, scorpion, spider, jellyfish, stone fish and others. Monovalent and polyvalent are two sub categories of anti-venom. According to World Health Organization (WHO), monovalent anti-venoms are also known as monospecific anti-venom. Monospecific anti-venoms are limited in use to a single species of venomous snake or to a few closely related species, whose venoms show clinically effective cross-neutralization with anti-venom. Polyvalent are anti-venoms which are obtained by fractionating the plasma from animals which are immunized by a mixture of venoms from several species of venomous snakes. Anti-Venom Market accounted for US$ 2.60 billion in 2020 and is estimated to be US$ 4.70 billion by 2030 and is anticipated to register a CAGR of 6.1%.
Global Antivenom Market By Type Dynamics
Treatment for snake bite
The demand for anti-venom treatment being the only authorized treatment for snake bite, as no option for alternative treatment is key factor drives growth of the anti-venom market. Increasing prevalence of scorpion bites, snake bites, and other animal or insect bites such as fish stings are other factors that propels the growth of the anti-venom market. Continuous research and development (R&D) provide advanced drugs and standard treatment for poisonous insect bite fuels the anti-venom market growth.
Approvals and launches of novel drugs
Approvals and launches of novel drugs in key regions are also expected to be a major factor that drives anti-venom market growth over the forecast period. For instance, in October 2018, Silanes Laboratories received the U.S. Food and Drug Administration (FDA) approval for Anavip, an anti-venom against the bite of snakes of the Crotalus family, which include the rattlesnake. However, high cost of anti-venom due to high production cost in some regions and lack in availability of essential anti-venom stock hampers growth of anti-venom market. For instance, according to the World Health Organization (WHO) in March 2018, in sub-Saharan Africa in 2010 and 2011, the direct cost of anti-venom alone ranged from US$ 55 to US$ 640 for an effective treatment.
High cost
The cost using recommended doses with the average cost being US$ 124.7 are not easily affordable by population in emerging economies, which hinders the growth of anti-venom market. The rapid development of the economic conditions across the globe is creating massive opportunities for the expansion of the anti-venom market.
Global Antivenom Market By Type Segmentation
The anti-venom market on the basis of type, animal type, distribution channel, and region.
On the basis of type, the anti-venom market has been segmented into monovalent and polyvalent. Based on animal type, the anti-venom market has been divided into snake, scorpion, spider and others. On the basis of distribution channel, the anti-venom market has been segmented into hospital, retail pharmacies and others.
Regional Insights:
For detailed understanding of market dynamics, the anti-venom market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the anti-venom market. The North America region is expected to dominate the anti-venom market and is estimated to retain its dominance over forecast period. The factors influencing the anti-venom market growth are the accelerating prevalence of scorpion bites and snake bites coupled with increasing expenditure on healthcare in North America region. The Europe is expected to dominate the anti-venom market due to the financial support by the government towards R&D activities attributed with the reimbursement scenario in this region. The market in Asia Pacific is expected to hold the largest market share in anti-venom market over the forecast period, owing to high incidence of snake bites in countries such as India and Bangladesh. For instance, according to the data published by Journal of the Association of Physicians of India, in 2017, around 50,000 people die in India annually, due to venomous snake bites. However, in rural areas of Asia Pacific regions such as India, Bangladesh, and Nepal, the adoption rate of anti-venom is quite low as people in these areas adopt traditional treatment than healthcare facilities over anti-venom. For instance, according to the data published by Journal of Pharmacology & Clinical Toxicology, in June 2018, in Bangladesh only 3% of snake bite victims visit hospital for their treatment.
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Type: Monovalent and Polyvalent By Animal Type: Snake, Scorpion, Spider and Others By Distribution Channel: Hospital, Retail Pharmacies and Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Detailed Segmentation:
Anti-Venom Market, By Type:
- Monovalent
- Polyvalent
Anti-Venom Market, By Animal Type:
- Snake
- Others
- Spider
- Scorpion
Anti-Venom Market, By Distribution Channel:
- Hospital
- Others
- Retail Pharmacies
Anti-Venom Market, By Region:
- North America
- Africa
- Africa Contrast Media Injectors Market, By Type
- Africa Contrast Media Injectors Market, By Animal Type
- Africa Contrast Media Injectors Market, By Distribution Channel
- Africa Contrast Media Injectors Market, By Country
- North Africa
- Central Africa
- South Africa
- Middle East
- Middle East Contrast Media Injectors Market, By Type
- Middle East Contrast Media Injectors Market, By Animal Type
- Middle East Contrast Media Injectors Market, By Distribution Channel
- Middle East Contrast Media Injectors Market, By Country
- GCC
- Israel
- Rest of Middle East
- Latin America
- Latin America Contrast Media Injectors Market, By Type
- Latin America Contrast Media Injectors Market, By Animal Type
- Latin America Contrast Media Injectors Market, By Distribution Channel
- Latin America Contrast Media Injectors Market, By Country
- Brazil
- Mexico
- Rest of Latin America
- Asia-Pacific
- Asia-Pacific Contrast Media Injectors Market, By Type
- Asia-Pacific Contrast Media Injectors Market, By Animal Type
- Asia-Pacific Contrast Media Injectors Market, By Distribution Channel
- Asia-Pacific Contrast Media Injectors Market, By Country
- China
- India
- Australia
- Japan
- South Korea
- Rest of Asia Pacific
- Europe
- Europe Contrast Media Injectors Market, By Type
- Europe Contrast Media Injectors Market, By Animal Type
- Europe Contrast Media Injectors Market, By Distribution Channel
- Europe Contrast Media Injectors Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- North America Contrast Media Injectors Market, By Type
- North America Contrast Media Injectors Market, By Animal Type
- North America Contrast Media Injectors Market, By Distribution Channel
- North America Contrast Media Injectors Market, By Country
- U.S.
- Canada
- Africa
Global Antivenom Market By Type Key Players
Some of the prominent players operating in the anti-venom market include Boston Scientific Corporation, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., Medline Industries Inc. and Rare Disease Therapeutics Inc. Advancements in the product as well as in manufacturing process are some trends witnessed in the anti-venom market. For instance, in 2018, Pfizer, Inc. worked with the U.S. Food and Drug Administration (FDA), to extend the expiration date of Antivenin’s Lot No. L67530 for an additional 12 months.
Global Antivenom Market By Type Company Profile
- Boston Scientific Corporation
- Rare Disease Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Medline Industries Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Incepta Pharmaceuticals Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Vins Bioproducts Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Haffkine Bio-Pharmaceutical Corporation Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Bharat Serums and Vaccines Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- CSL Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Rare Disease Therapeutics Inc.
Global Antivenom Market By Type Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Anti-Venom Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By Animal Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Type, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Monovalent
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Polyvalent
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By Animal Type, 2020 – 2030, (US$ Bn)
- Overview Snake, Scorpion, Spider and Others
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Snake
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Scorpion
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Spider
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview Snake, Scorpion, Spider and Others
- Market Segmentation, By End-User 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Retail Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Market, By Region, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Animal Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Animal Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Animal Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Animal Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Animal Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Boston Scientific Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- CSL Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Bharat Serums and Vaccines Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Haffkine Bio-Pharmaceutical Corporation Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Vins Bioproducts Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Incepta Pharmaceuticals Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Medline Industries Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Rare Disease Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Boston Scientific Corporation
The Last Word
-
- Future Impact
- About Us
- Contact
FAQs
The anti-venom market on the basis of type, animal type, distribution channel, and region.
The demand for anti-venom treatment being the only authorized treatment for snake bite, as no option for alternative treatment is key factor drives growth of the anti-venom market.
North America region is expected to dominate the anti-venom market and is estimated to retain its dominance over forecast period.
Some of the prominent players operating in the anti-venom market include Boston Scientific Corporation, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., Medline Industries Inc. and Rare Disease Therapeutics Inc.